Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
DRUG

auto-HSCT-Supported Dose-Dense Chemotherapy With Adebrelimab

"Induction:~Two 21-day cycles of standard-dose etoposide 80-100 mg/m² on days 1-3 and carboplatin AUC 5-6 on day 1.~Those without disease progression will advance to consolidation treatment.~Consolidation:~Stem cell mobilization with G-CSF will be start when white blood cell count is at its nadir post-chemotherapy.~After recovery, peripheral blood stem cells will be collected via apheresis, evaluated, and cryopreserved if adequate.~Dose-dense etoposide 160-200 mg/m² on days 1-3 and carboplatin AUC 10-12 on day 1 for two 21-day cycles.~Within 48-72 hours after the first cycle, autologous peripheral blood stem cells will be reinfused with G-CSF.~Further consolidation will depend on hematopoietic recovery with standard-dose EC plus adebrelimab 1200 mg on day 1 for four 21-day cycles.~Maintenance:~Adebrelimab 1200 mg every 21 days will be given until disease progression, intolerable toxicity, death, patient withdrawal, or investigator decision."

All Listed Sponsors
lead

Zhou Chengzhi

OTHER